Because many metastatic lesions in bone are considered mixed (although the lytic or the blastic phase may be predominant), therapeutic strategies that target both the osteolytic and osteoblastic components may be necessary to inhibit progression of a skeletal metastatic lesion effectively.
These results show that modulation towards an M2 phenotype may inhibit plaque progression, reflect plaque regression and holds promise that it may also promote plaque regression in an advanced plaque.
Conversely, immune activation via homeostatic proliferation is important for the rejection of tumors and IL-21 administration may inhibit the progression of metastatic melanoma and renal carcinoma in clinical protocols [60], [61].
MEG3 may inhibit tumor progression by inhibiting angiogenesis [ 10].
Whenever therapies succeed in reversing the sign of (β−1), they may inhibit disease progression.
Genistein may inhibit cancer progression by inducing apoptosis or inhibiting proliferation, but mechanisms are not well understood.
In addition, SOCS1 may inhibit the progression of hematopoietic malignancies, because SOCS1 in vivo is preferentially expressed in lymphoid organs.
In normal cells and early carcinogenesis CLU may inhibit tumour progression, whereas it may favour survival advantage in advanced tumours [ 42].
Targeting specific subsets of cellular PHB may have therapeutic potential, and reducing mitochondrial PHB and/or increasing nuclear PHB may inhibit tumor progression.
